<DOC>
	<DOCNO>NCT02822547</DOCNO>
	<brief_summary>Patients receive Peginterferon alfa-2a accord standard medical practice observation period 12 week</brief_summary>
	<brief_title>Study Treatment Pegylated Interferon Alfa 2a ( Pegasys® ) Korean Chronic Hepatitis B ( CHB ) Adults</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>History HBsAg positive 6 month HBeAgpositive HBeAgnegative within 8 week Serum AST ALT ≥ 80 IU/L HBeAg positive patient : Serum HBV DNA ≥ 1.0 X 10^5 copies/mL ( 20,000 IU/mL ) HBeAgnegative patient : serum HBV DNA ≥ 1.0 X 10^4 copies/mL ( 2,000 IU/mL ) History antiviral therapy Chronic hepatitis B within 6 month study enrollment Prior treatment interferon Presence viral coinfections ( hepatitis C , hepatitis delta , human immunodeficiency virus ) Other chronic liver disease decompensated liver disease platelet &lt; 90,000/mm3 absolute neutrophil count &lt; 1,500 mm3 Pregnant lactate woman History Organ transplantation Treatment immunosuppressive/immunomodulatory agent within 6 month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>